LC
RUBY

Lindbrook Capital’s Rubius Therapeutics, Inc RUBY Stock Holding History

Lindbrook Capital’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-87
Closed – – 2866
2022
Q1 		$0 Sell
87
-99
-53% -$629 ﹤0.01% 2660
2021
Q4 		$2K Hold
186
– – ﹤0.01% 1852
2021
Q3 		$3K Hold
186
– – ﹤0.01% 1472
2021
Q2 		$5K Hold
186
– – ﹤0.01% 1325
2021
Q1 		$5K Hold
186
– – ﹤0.01% 1293
2020
Q4 		$1K Buy
+186
New +$1.1K ﹤0.01% 1737

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lindbrook Capital's RUBY Position: Q2 2022 in Review

Lindbrook Capital sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 87 shares.

Lindbrook Capital first reported a position in RUBY in Q4 2020 and held it in 6 quarters. The position peaked at $5K in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Lindbrook Capital reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Lindbrook Capital sold 87 Rubius Therapeutics, Inc shares in Q2 2022.
  • Lindbrook Capital first reported a position in Rubius Therapeutics, Inc in Q4 2020 and held it in 6 quarters.
  • Lindbrook Capital's Rubius Therapeutics, Inc position peaked at $5K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Lindbrook Capital's 13F filing for Q2 2022, filed 1 Aug 2022.